Merck Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing

Merck, a leading science and technology company, announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative. The effort will provide vaccine process development training courses within TRANSVAC2, a collaborative infrastructure project under Horizon 2020.


See full press release: https://www.merckgroup.com/en/news/transvac2-program-joining-20-05-2019.html


TRANSVAC2-program-to-advance-vaccine-development-and-manufacturing-EN
.pdf
Download PDF • 78KB

TRANSVAC2 has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964.

This communication reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.